Chronic Spontaneous Urticaria: New Insights Into Mast Cells and Targeted Therapies
Clinical Summary
Chronic Spontaneous Urticaria (CSU): Mast Cell–Targeted Therapies and Earlier Treatment Escalation
-
CSU pathophysiology: Management is shifting beyond histamine blockade toward therapies that target mast cell activation, addressing upstream disease mechanisms rather than only downstream symptoms.
-
Evolving treatment landscape: Up to ~50% of patients remain symptomatic despite standard or up-titrated non-sedating antihistamines. In addition to omalizumab (FDA-approved since 2014), newer FDA-approved biologic and oral targeted therapies are expanding options for refractory disease.
-
Clinical management: Prioritize early treatment escalation when antihistamines fail rather than allowing persistent disease. Familiarity with newer FDA-approved agents can improve long-term disease control, quality of life, and allow more patients to remain under dermatologic care.
Reviewed by Riya Gandhi, MA, Associate Editor of Immunology Group
Dr Christina Feser discusses evolving insights into the pathophysiology of chronic spontaneous urticaria (CSU), including the central role of mast cell activation and the shift beyond antihistamine-focused treatment. Learn how newly approved biologics and targeted therapies are expanding options for patients with refractory disease, improving long-term symptom control, and enhancing quality of life through more individualized management strategies.
Transcript
Hi, my name is Dr Christina Feser. I'm a board-certified dermatologist and principal investigator in Nashville, Tennessee.
What are the most important updates in our understanding of the pathophysiology of chronic spontaneous urticaria that are influencing treatment today?
Dr Feser: The pathophysiology can really be complex and we're starting to gain more understanding for what is driving or influencing the chronic disease state that we see in CSU or chronic spontaneous urticaria. And we know that we need to address now more than just histamine or really treating those downstream mediated effects as to what is driving the development of these lesions in general overall. The role of the mast cells is extremely important and really new and novel agents that are in development and currently FDA approved for the management of chronic spontaneous urticaria are helping to target the mast cell itself to prevent mast cell activation, essentially turning off the mast cell activity and preventing the development of the lesions that are common in chronic spontaneous urticaria.
How are newer therapies—particularly biologics or targeted agents—changing the management approach for patients who are refractory to antihistamines?
Dr Feser: We know that a lot of these patients, up to almost half of patients, on antihistamines or even up-titrated doses of our standard non-sedating antihistamines, remain with clinical symptoms even despite the therapy. Now, this presents often in our dermatology clinics, and it often presents to our allergy colleagues as well, too.
In the past, our options were fairly limited as far as FDA-approved agents to treat and manage our CSU patients. There is omalizumab, which is a biologic that's been approved since 2014, it's been around but not every dermatologist is comfortable prescribing and administering this agent in office due to potential adverse effects associated with the medication, and these patients in turn have been referred out to our allergy colleagues for further management as well. Not all these patients respond to these agents.
But now with the recent approvals, we have some FDA, 2 additional new approved agents right now. One, we're familiar with using frequently in dermatology, as it's been in the space for a long time for our atopic dermatitis patients. And two, an oral agent that's something that we can also offer our patients that can prove safe, clinically effective, and lead to a lot of clinical improvement for these patients to really bring these patients back into the dermatology world and to keep these patients with us providing better options to get better control beyond our standard antihistamines.
What practical strategies can clinicians use to better individualize treatment and improve long-term disease control and patient quality of life?
Dr Feser: The quality of life is number one for patients with CSU. The lesions themselves are uncomfortable, they can be painful, and they can be really debilitating, especially when they occur with increased frequency. Standard antihistamines, they're their go-to strategy. It's what we start with. But it really is not waiting too long for the disease state to continue to persist or to worsen, even if patients are on standard therapy and not improving. It's important to advance therapy sooner than later to get these patients symptomatic relief and under good disease control. And really having more agents available of which we're comfortable with that we've utilized in clinical practice for potentially other conditions could be something that we could more quickly advance therapy when good disease state is not under control. Or also having some additional agent available such as the oral treatment options to really offer patients a new effective treatment to help manage their CSU.
Are there any tips or insights you would like to share regarding chronic spontaneous urticaria?
Dr Feser: I would say when managing CSU, it's difficult. It's one of those things that walks in the door and we know that patients often don't respond to our topical or our oral antihistamine-based strategies. So really speak with these patients, escalate therapy, get comfortable with the agents that are FDA-approved, and really do the best to get better disease control in an efficient manner.
